Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Cardiac Fibrosis in Proteotoxic Cardiac Disease is Dependent Upon Myofibroblast TGF -β Signaling.

Bhandary B, Meng Q, James J, Osinska H, Gulick J, Valiente-Alandi I, Sargent MA, Bhuiyan MS, Blaxall BC, Molkentin JD, Robbins J.

J Am Heart Assoc. 2018 Oct 16;7(20):e010013. doi: 10.1161/JAHA.118.010013.

2.

Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart.

Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, Sargent MA, Prasad V, Valiente-Alandi I, Blaxall BC, Molkentin JD.

J Clin Invest. 2018 May 1;128(5):2127-2143. doi: 10.1172/JCI98215. Epub 2018 Apr 16.

3.

Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Valiente-Alandi I, Potter SJ, Salvador AM, Schafer AE, Schips T, Carrillo-Salinas F, Gibson AM, Nieman ML, Perkins C, Sargent MA, Huo J, Lorenz JN, DeFalco T, Molkentin JD, Alcaide P, Blaxall BC.

Circulation. 2018 Sep 18;138(12):1236-1252. doi: 10.1161/CIRCULATIONAHA.118.034609.

PMID:
29653926
4.

Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.

Travers JG, Kamal FA, Valiente-Alandi I, Nieman ML, Sargent MA, Lorenz JN, Molkentin JD, Blaxall BC.

J Am Coll Cardiol. 2017 Aug 22;70(8):958-971. doi: 10.1016/j.jacc.2017.06.049.

5.

Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.

Tomita K, Kohli R, MacLaurin BL, Hirsova P, Guo Q, Sanchez LHG, Gelbard HA, Blaxall BC, Ibrahim SH.

JCI Insight. 2017 Aug 3;2(15). pii: 94488. doi: 10.1172/jci.insight.94488. [Epub ahead of print]

6.

G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Schafer AE, Blaxall BC.

J Cardiovasc Pharmacol. 2017 Jul;70(1):10-15. doi: 10.1097/FJC.0000000000000475. Review.

7.

Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.

Rudomanova V, Blaxall BC.

Biochim Biophys Acta Mol Basis Dis. 2017 Aug;1863(8):1883-1892. doi: 10.1016/j.bbadis.2017.01.020. Epub 2017 Jan 25. Review.

8.

G Protein-Coupled Receptor-G-Protein βγ-Subunit Signaling Mediates Renal Dysfunction and Fibrosis in Heart Failure.

Kamal FA, Travers JG, Schafer AE, Ma Q, Devarajan P, Blaxall BC.

J Am Soc Nephrol. 2017 Jan;28(1):197-208. doi: 10.1681/ASN.2015080852. Epub 2016 Jun 13.

9.

GRK2 in Lymphocytes: Expanding the Arsenal of Heart Failure Prognostics.

Travers JG, Schafer AE, Blaxall BC.

Circ Res. 2016 Apr 1;118(7):1049-51. doi: 10.1161/CIRCRESAHA.116.308542. No abstract available.

10.

From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.

Bernardo BC, Blaxall BC.

Heart Lung Circ. 2016 May;25(5):425-34. doi: 10.1016/j.hlc.2016.01.002. Epub 2016 Jan 19. Review.

11.

Cardiac Fibrosis: The Fibroblast Awakens.

Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC.

Circ Res. 2016 Mar 18;118(6):1021-40. doi: 10.1161/CIRCRESAHA.115.306565. Review.

12.

Extracellular matrix-mediated cellular communication in the heart.

Valiente-Alandi I, Schafer AE, Blaxall BC.

J Mol Cell Cardiol. 2016 Feb;91:228-37. doi: 10.1016/j.yjmcc.2016.01.011. Epub 2016 Jan 14. Review.

13.

RNA extraction from healthy and failing human myocardium: a comparative evaluation.

Hong YH, Martin LA, Mulvaney JM, Burhans MS, Blaxall BC, Hinton RB.

Biopreserv Biobank. 2015 Apr;13(2):123-30. doi: 10.1089/bio.2014.0062. Epub 2015 Mar 31.

PMID:
25825942
14.

Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression.

Kamal FA, Mickelsen DM, Wegman KM, Travers JG, Moalem J, Hammes SR, Smrcka AV, Blaxall BC.

J Am Coll Cardiol. 2014 Jun 17;63(23):2549-2557. doi: 10.1016/j.jacc.2014.02.587. Epub 2014 Apr 2.

15.

Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013.

Barbato E, Lara-Pezzi E, Stolen C, Taylor A, Barton PJ, Bartunek J, Iaizzo P, Judge DP, Kirshenbaum L, Blaxall BC, Terzic A, Hall JL.

J Cardiovasc Transl Res. 2014 Jul;7(5):518-25. Review.

16.

Embracing bias: β1-adrenergic receptor-biased ligands and nuclear miRNA processing.

Kamal FA, Travers JG, Blaxall BC.

Circ Res. 2014 Feb 28;114(5):742-5. doi: 10.1161/CIRCRESAHA.114.303237. No abstract available. Erratum in: Circ Res. 2014 Mar 28;114(7):e33.

PMID:
24577958
17.

Mena associates with Rac1 and modulates connexin 43 remodeling in cardiomyocytes.

Ram R, Wescott AP, Varandas K, Dirksen RT, Blaxall BC.

Am J Physiol Heart Circ Physiol. 2014 Jan 1;306(1):H154-9. doi: 10.1152/ajpheart.00749.2013. Epub 2013 Nov 1.

18.

Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury.

Oikawa M, Wu M, Lim S, Knight WE, Miller CL, Cai Y, Lu Y, Blaxall BC, Takeishi Y, Abe J, Yan C.

J Mol Cell Cardiol. 2013 Nov;64:11-9. doi: 10.1016/j.yjmcc.2013.08.003. Epub 2013 Aug 27.

19.

An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure.

Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J.

Circ Res. 2013 Aug 16;113(5):553-61. doi: 10.1161/CIRCRESAHA.113.301225. Epub 2013 Jul 12.

20.

Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.

Belmonte SL, Ram R, Mickelsen DM, Gertler FB, Blaxall BC.

Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H875-84. doi: 10.1152/ajpheart.00342.2013. Epub 2013 Jul 5.

Supplemental Content

Loading ...
Support Center